Trial | NCT04622826  Report issue

Title

plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients
Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    50
Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms within seven days from the beginning of symptoms.

Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.
Study Started
May 15
2020
Primary Completion
Dec 31
2020
Anticipated
Study Completion
Dec 31
2020
Anticipated
Last Update
Nov 10
2020

Biological immune plasma

immune covid 19 plasma infusion

sequential immune plasma infused patients Experimental

immune covid 19 plasma infusion

Criteria 

Inclusion Criteria:

> 18 years
hospitalized patients with positive covid-19 swab with respiratory symptoms and CT confirmation of covid-19 chest disease admitted to non ITU recovery area.
informed consent for plasma infusion
informed consent to blood samples storing for future studies.

Exclusion Criteria:

pregnant or breastfeeding female patient or planning for a pregnancy in the period of the study

immunoglobulin infusion in the last month

contraindication to transfusion or previous adverse reaction
No Results Posted